20.500.12556/DiRROS-19022 PD-L1 expression in squamous-cell carcinoma and adenocarcinoma of the lung With introduction of immunotherapy (IT) into the treatment of advanced non-small-cell lung cancer (NSCLC), a need for predictive biomarker became apparent. Programmed death ligand 1 (PD-L1) protein expression is most widely explored predictive marker for response to IT. We assessed PD-L1 expression in tumor cells (TC) and immune cells (IC) of squamous-cell carcinoma (SCC) and adenocarcinoma (AC) patients. We obtained 54 surgically resected tumor specimens and assessed PD-L1 expression by immunohistochemistry after staining them with antibody SP142 (Ventana, USA). Clinicopathological characteristics were acquired from the hospital registry database. Results were analyzed according to cut-off values of % 5% and % 10% of PD-L1 expression on either TC or IC. 29 (54%) samples were AC and 25 (46%) were SCC. PD-L1 expression was significantly higher in TC of SCC compared to AC at both cut-off values (52% vs. 17%, p = 0.016 and 52% vs. 14%, p = 0.007, respectively) no difference in PD-L1 expression in IC of SCC and AC was found. In AC alone, PD-L1 expression was significantly higher in IC compared to TC at both cut-off values (72% vs. 17%, p < 0.001 and 41% vs. 14%, p = 0.008, respectively), while no significant difference between IC and TC PD-L1 expression was revealed in SCC. Our results suggest a significantly higher PD-L1 expression in TC of SCC compared to AC, regardless of the cut-off value. PD-L1 expression in IC is high in both histological subtypes of NSCLC, and adds significantly to the overall positivity of AC but not SCC. lung cancer squamous-cell lung cancer adenocarcinoma tumor cells immune cells PD-L1 expression true false true Association of Radiology and Oncology Ljubljana Angleški jezik Slovenski jezik by Authors Neznano 2024-05-31 14:52:23 2024-05-31 14:52:23 2024-06-01 03:35:37 0000-00-00 00:00:00 2017 0 0 str. 357-362, XI no. 3 Vol. 51 2017 0000-00-00 Zaloznikova Objavljeno NiDoloceno 0000-00-00 0000-00-00 2017-01-01 616-006.6:615.37 1318-2099 10.1515/raon-2017-0037 4381553 https://www.degruyter.com/view/j/raon.2017.51.issue-3/raon-2017-0037/raon-2017-0037.xml 1 a0fee138-1f4c-11ef-9c9e-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=26100 https://www.degruyter.com/downloadpdf/j/raon.2017.51.issue-3/raon-2017-0037/raon-2017-0037.pdf 1 a1502a8c-1f4c-11ef-9c9e-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=26101 RAZ_Janzic_Urska_2017.pdf RAZ_Janzic_Urska_2017.pdf 1 6537F7C50DB083FDA8A916970261F1CC f56150b87a5851e95e5579503bc5280fd712028e60c3d4e090134f0a6540c498 c6280999-1f4c-11ef-9c9e-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=26102 Onkološki inštitut Ljubljana 0 0 0